Titan Medical Inc. Announces Results for Fiscal Year Ended December 31, 2013

Titan Medical Inc. ("Titan" or the "Company") (TSX VENTURE:TMD)(OTCQX:TITXF)
announced today its results for the fiscal year ended December 31, 2013.


The Audited Financial Statements and Management's Discussion and Analysis for
the year ended December 31, 2013 may be viewed on SEDAR at www.sedar.com.


John Hargrove, Chairman and Chief Executive Officer of Titan Medical Inc.,
commented, "2013 was a significant year for Titan. In August we accepted
delivery of our initial functional prototype of the SPORT(TM) Surgical System.
We followed this major achievement with a number of announcements and videos to
showcase the dexterity and functionality of the SPORT Surgical System. In
November we undertook our initial tissue test which was very successful in
assessing and measuring the functionality of the SPORT Surgical System. I am
very pleased with the progress we have made and continue to make. We continue to
meet our milestones and remain on track for commercialization in 2015."


Operational Highlights



--  On August 27, 2013, the Company announced that it had successfully
    completed development of a functional prototype of its SPORT Surgical
    System. 
--  On September 17, 2013, the Company announced that Dr. Dennis Fowler had
    accepted the position of Director of Clinical Affairs and would be
    responsible for Titan's regulatory approval process plan, including its
    pre-clinical and clinical testing strategy. This plan is expected to
    reduce the regulatory approval timeline. 
--  On October 9, 2013, the Company announced that it had posted a video on
    its website illustrating the impressive dexterity of the "snake-like"
    robotic instruments of its SPORT Surgical System. 
--  On October 16, 2103, the Company announced that it had posted a video on
    its website demonstrating the impressive preciseness and reliability of
    the robotic instruments of its SPORT Surgical System. 
--  On November 11, 2013, the Company announced that it had recently started
    tissue testing with its SPORT Surgical System.



Financial Highlights



--  Cash and cash equivalents at December 31, 2013 totaled $2,601,664,
    compared to $4,617,016 at December 31, 2012. 
--  Net loss for the fiscal year ended December 31, 2013 was $9,343,749,
    compared to a net loss of $7,757,244, for the fiscal year ended December
    31, 2012. The increased loss in the year ended December 31, 2013
    compared to December 31, 2012 reflects the increased focus on the
    ongoing development of the SPORT Surgical System. 
--  The Company's Research and Development expenses for the fiscal year
    ended December 31, 2013 were $5,514,737, compared to $4,638,239, for the
    year ended December 31, 2012. The increase in R&D expenditures reflects
    the advancement in the development of the SPORT Surgical System. 
--  On March 13, 2013 the Company completed a public offering of 6,260,763
    units at a price of $1.05 per Unit for Gross proceeds of $6,573,801. 
--  On February 19, 2014 the Company completed a public offering of
    9,142,500 Units at a price of $1.40 per Unit for gross proceeds of
    $12,799,500.



About Titan Medical Inc.

Titan Medical Inc. is a Canadian public company (TSX VENTURE:TMD)(OTCQX:TITXF)
focused on the design and development of the SPORT Surgical System, a robotic
surgical system for application in minimally invasive surgery ("MIS"). The SPORT
Surgical System, currently under development, comprises a surgeon-controlled
robotic platform that includes a 3D vision system and interactive instruments
for performing MIS procedures, and a surgeon workstation that provides the
surgeon with an interface to the robotic platform for controlling the
interactive instruments and providing a 3D endoscopic view of inside a patient's
body during MIS procedures. The SPORT Surgical System is being designed to
expand robotic surgery into areas of surgical specialties and simple and complex
procedures that are currently under-serviced, and to allow surgeons to perform
procedures within small to medium size surgical spaces such as general surgery
and cholecystectomy. For more information, visit the Company's website at
www.titanmedicalinc.com.


Forward-Looking Statements

This news release contains "forward-looking statements" which reflect the
current expectations of management of the Company's future growth, results of
operations, performance and business prospects and opportunities. Wherever
possible, words such as "may", "would", "could", "will", "anticipate",
"believe", "plan", "expect", "intend", "estimate", "potential for" and similar
expressions have been used to identify these forward-looking statements. These
statements reflect management's current beliefs with respect to future events
and are based on information currently available to management. Forward-looking
statements involve significant risks, uncertainties and assumptions.


Many factors could cause the Company's actual results, performance or
achievements to be materially different from any future results, performance or
achievements that may be expressed or implied by such forward-looking
statements, including, without limitation, those listed in the "Risk Factors"
section of the Company's Annual Information Form dated April 10, 2013 (which may
be viewed at www.sedar.com). Should one or more of these risks or uncertainties
materialize, or should assumptions underlying the forward looking statements
prove incorrect, actual results, performance or achievements may vary materially
from those expressed or implied by the forward-looking statements contained in
this news release. These factors should be considered carefully and prospective
investors should not place undue reliance on the forward-looking statements.
Although the forward-looking statements contained in the news release are based
upon what management currently believes to be reasonable assumptions, the
Company cannot assure prospective investors that actual results, performance or
achievements will be consistent with these forward-looking statements.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Titan Medical Inc.
John Hargrove
Chairman and Chief Executive Officer
[phone] (ext. 151)
[e-mail]
www.titanmedicalinc.com


Beverly Brooks
Investor Relations
[phone]
[e-mail]